GALNS: Preliminary Extension study data

Preliminary data from the ongoing MOR-100 extension of the open-label, dose-escalation Phase I/II MOR-002 trial in about 15 patients showed that weekly

Read the full 229 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE